Chinese General Practice ›› 2023, Vol. 26 ›› Issue (27): 3435-3440.DOI: 10.12114/j.issn.1007-9572.2023.0049
Special Issue: 乳腺癌最新文章合集; 肿瘤最新文章合集
• Article • Previous Articles Next Articles
Received:
2022-12-12
Revised:
2023-02-15
Published:
2023-09-20
Online:
2023-03-01
Contact:
XU Lingyun
通讯作者:
许凌云
作者简介:
作者贡献:裴蓓提出研究构思;成琳、许凌云进行可行性分析、研究指导;裴蓓、成琳参与数据采集、整理;裴蓓负责数据的收集、统计分析及撰写论文,对论文负责;许凌云进行写作指导及论文修订。
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0049
组别 | 例数 | 年龄(岁) | BMI (kg/m2) | 吸烟史〔例(%)〕 | 月经状态〔例(%)〕 | TNM分期〔例(%)〕 | 淋巴结状态〔例(%)〕 | 组织学分级〔例(%)〕 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
绝经前 | 绝经后 | Ⅱ | Ⅲa | Ⅲb | N0 | N1 | N2 | N3 | G1 | G2 | G3 | |||||
对照组 | 46 | 61.2±7.4 | 23.7±4.1 | 5(10.9) | 19(41.3) | 27(58.7) | 5(10.9) | 20(43.5) | 21(45.6) | 8(17.4) | 23(50.0) | 10(21.7) | 5(10.9) | 1(2.2) | 20(43.5) | 25(54.3) |
研究组 | 46 | 60.2±8.2 | 24.1±3.4 | 4(8.7) | 21(45.6) | 25(54.4) | 7(15.2) | 19(41.3) | 20(43.5) | 9(19.6) | 21(45.6) | 9(19.6) | 7(15.2) | 0 | 18(39.1) | 28(60.9) |
χ2(t)值 | 0.009a | 0.003a | 0.123 | 0.177 | 0.383 | 0.536 | 1.275 | |||||||||
P值 | 0.924 | 0.956 | 0.725 | 0.674 | 0.826 | 0.911 | 0.529 |
Table 1 Comparison of general information of patients between the two groups
组别 | 例数 | 年龄(岁) | BMI (kg/m2) | 吸烟史〔例(%)〕 | 月经状态〔例(%)〕 | TNM分期〔例(%)〕 | 淋巴结状态〔例(%)〕 | 组织学分级〔例(%)〕 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
绝经前 | 绝经后 | Ⅱ | Ⅲa | Ⅲb | N0 | N1 | N2 | N3 | G1 | G2 | G3 | |||||
对照组 | 46 | 61.2±7.4 | 23.7±4.1 | 5(10.9) | 19(41.3) | 27(58.7) | 5(10.9) | 20(43.5) | 21(45.6) | 8(17.4) | 23(50.0) | 10(21.7) | 5(10.9) | 1(2.2) | 20(43.5) | 25(54.3) |
研究组 | 46 | 60.2±8.2 | 24.1±3.4 | 4(8.7) | 21(45.6) | 25(54.4) | 7(15.2) | 19(41.3) | 20(43.5) | 9(19.6) | 21(45.6) | 9(19.6) | 7(15.2) | 0 | 18(39.1) | 28(60.9) |
χ2(t)值 | 0.009a | 0.003a | 0.123 | 0.177 | 0.383 | 0.536 | 1.275 | |||||||||
P值 | 0.924 | 0.956 | 0.725 | 0.674 | 0.826 | 0.911 | 0.529 |
组别 | 例数 | CR | PR | SD | PD | 临床有效率 | 有效控制率 |
---|---|---|---|---|---|---|---|
对照组 | 46 | 5(10.9) | 15(32.6) | 12(26.1) | 14(30.4) | 20(43.5) | 32(69.6) |
研究组 | 46 | 12(26.1) | 22(47.8) | 7(15.2) | 5(10.9) | 34(73.9) | 41(89.1) |
χ2值 | 3.536 | 2.215 | 1.658 | 4.301 | 4.091 | 4.182 | |
P值 | 0.060 | 0.137 | 0.198 | 0.052 | 0.043 | 0.041 |
Table 2 Evaluation of the efficacy of patients in both groups after treatment
组别 | 例数 | CR | PR | SD | PD | 临床有效率 | 有效控制率 |
---|---|---|---|---|---|---|---|
对照组 | 46 | 5(10.9) | 15(32.6) | 12(26.1) | 14(30.4) | 20(43.5) | 32(69.6) |
研究组 | 46 | 12(26.1) | 22(47.8) | 7(15.2) | 5(10.9) | 34(73.9) | 41(89.1) |
χ2值 | 3.536 | 2.215 | 1.658 | 4.301 | 4.091 | 4.182 | |
P值 | 0.060 | 0.137 | 0.198 | 0.052 | 0.043 | 0.041 |
组别 | 例数 | CD3+(%) | CD4+(%) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
治疗前 | 治疗后 | t配对值 | P值 | 治疗前 | 治疗后 | t配对值 | P值 | |||||
对照组 | 46 | 40.12±3.45 | 55.32±4.02 | 21.342 | 0.001 | 30.02±3.87 | 33.23±2.79 | 8.546 | 0.001 | |||
研究组 | 46 | 41.21±4.02 | 66.31±4.65 | 28.347 | 0.001 | 30.62±4.01 | 38.53±5.03 | 11.326 | 0.001 | |||
t值 | 0.213 | 13.242 | 0.413 | 9.324 | ||||||||
P值 | 0.876 | 0.001 | 0.765 | 0.013 | ||||||||
组别 | CD8+(%) | CD4+/CD8+ | IL-6(μg/L) | |||||||||
治疗前 | 治疗后 | t配对值 | P值 | 治疗前 | 治疗后 | t配对值 | P值 | 治疗前 | 治疗后 | t配对值 | P值 | |
对照组 | 34.52±2.89 | 28.48±3.45 | 16.349 | 0.001 | 0.92±0.15 | 1.35±0.20 | 8.534 | 0.001 | 4.24±1.02 | 3.03±1.23 | 11.212 | 0.001 |
研究组 | 33.82±4.22 | 24.63±3.43 | 20.398 | 0.001 | 1.05±0.18 | 1.65±0.18 | 14.231 | 0.001 | 4.02±0.98 | 2.01±0.87 | 15.237 | 0.001 |
t值 | 0.335 | 10.426 | 0.117 | 3.213 | 0.786 | 9.234 | ||||||
P值 | 0.798 | 0.010 | 0.912 | 0.011 | 0.654 | 0.003 | ||||||
组别 | IL-8(μg/L) | TNF-α(μg/L) | IFN-γ(μg/L) | |||||||||
治疗前 | 治疗后 | t配对值 | P值 | 治疗前 | 治疗后 | t配对值 | P值 | 治疗前 | 治疗后 | t配对值 | P值 | |
对照组 | 36.35±3.41 | 15.64±3.56 | 24.542 | 0.001 | 8.06±1.87 | 7.05±1.37 | 7.845 | 0.001 | 10.76±2.34 | 8.65±2.23 | 13.234 | 0.001 |
研究组 | 35.88±4.22 | 10.32±2.49 | 29.765 | 0.001 | 7.95±1.91 | 6.11±2.01 | 9.113 | 0.001 | 9.88±2.04 | 7.34±1.98 | 15.623 | 0.001 |
t值 | 0.203 | 14.233 | 0.187 | 5.323 | 0.196 | 4.899 | ||||||
P值 | 0.866 | 0.001 | 0.913 | 0.012 | 0.900 | 0.011 |
Table 3 Comparison of the levels of T lymphocyte and inflammatory factors between the two groups
组别 | 例数 | CD3+(%) | CD4+(%) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
治疗前 | 治疗后 | t配对值 | P值 | 治疗前 | 治疗后 | t配对值 | P值 | |||||
对照组 | 46 | 40.12±3.45 | 55.32±4.02 | 21.342 | 0.001 | 30.02±3.87 | 33.23±2.79 | 8.546 | 0.001 | |||
研究组 | 46 | 41.21±4.02 | 66.31±4.65 | 28.347 | 0.001 | 30.62±4.01 | 38.53±5.03 | 11.326 | 0.001 | |||
t值 | 0.213 | 13.242 | 0.413 | 9.324 | ||||||||
P值 | 0.876 | 0.001 | 0.765 | 0.013 | ||||||||
组别 | CD8+(%) | CD4+/CD8+ | IL-6(μg/L) | |||||||||
治疗前 | 治疗后 | t配对值 | P值 | 治疗前 | 治疗后 | t配对值 | P值 | 治疗前 | 治疗后 | t配对值 | P值 | |
对照组 | 34.52±2.89 | 28.48±3.45 | 16.349 | 0.001 | 0.92±0.15 | 1.35±0.20 | 8.534 | 0.001 | 4.24±1.02 | 3.03±1.23 | 11.212 | 0.001 |
研究组 | 33.82±4.22 | 24.63±3.43 | 20.398 | 0.001 | 1.05±0.18 | 1.65±0.18 | 14.231 | 0.001 | 4.02±0.98 | 2.01±0.87 | 15.237 | 0.001 |
t值 | 0.335 | 10.426 | 0.117 | 3.213 | 0.786 | 9.234 | ||||||
P值 | 0.798 | 0.010 | 0.912 | 0.011 | 0.654 | 0.003 | ||||||
组别 | IL-8(μg/L) | TNF-α(μg/L) | IFN-γ(μg/L) | |||||||||
治疗前 | 治疗后 | t配对值 | P值 | 治疗前 | 治疗后 | t配对值 | P值 | 治疗前 | 治疗后 | t配对值 | P值 | |
对照组 | 36.35±3.41 | 15.64±3.56 | 24.542 | 0.001 | 8.06±1.87 | 7.05±1.37 | 7.845 | 0.001 | 10.76±2.34 | 8.65±2.23 | 13.234 | 0.001 |
研究组 | 35.88±4.22 | 10.32±2.49 | 29.765 | 0.001 | 7.95±1.91 | 6.11±2.01 | 9.113 | 0.001 | 9.88±2.04 | 7.34±1.98 | 15.623 | 0.001 |
t值 | 0.203 | 14.233 | 0.187 | 5.323 | 0.196 | 4.899 | ||||||
P值 | 0.866 | 0.001 | 0.913 | 0.012 | 0.900 | 0.011 |
组别 | 例数 | PD-L1阳性细胞百分比≥25%比例 | PD-1阳性细胞百分比≥65%比例 | FoxP3阳性细胞百分比≥0.45%比例 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
治疗前 | 治疗后 | χ2值 | P值 | 治疗前 | 治疗后 | χ2值 | P值 | 治疗前 | 治疗后 | χ2值 | P值 | ||
对照组 | 46 | 15(32.61) | 18(39.13) | 0.425 | 0.514 | 14(30.43) | 17(36.96) | 0.438 | 0.508 | 32(69.57) | 28(60.87) | 0.767 | 0.381 |
研究组 | 46 | 14(30.43) | 28(60.87) | 8.587 | 0.003 | 14(30.43) | 27(58.70) | 7.436 | 0.006 | 33(71.74) | 18(39.13) | 9.900 | 0.002 |
χ2值 | 0.050 | 4.348 | 0.001 | 4.356 | 0.052 | 4.348 | |||||||
P值 | 0.822 | 0.037 | 0.999 | 0.037 | 0.819 | 0.037 |
Table 4 Comparison of tumor microenvironment indicators levels between the two groups
组别 | 例数 | PD-L1阳性细胞百分比≥25%比例 | PD-1阳性细胞百分比≥65%比例 | FoxP3阳性细胞百分比≥0.45%比例 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
治疗前 | 治疗后 | χ2值 | P值 | 治疗前 | 治疗后 | χ2值 | P值 | 治疗前 | 治疗后 | χ2值 | P值 | ||
对照组 | 46 | 15(32.61) | 18(39.13) | 0.425 | 0.514 | 14(30.43) | 17(36.96) | 0.438 | 0.508 | 32(69.57) | 28(60.87) | 0.767 | 0.381 |
研究组 | 46 | 14(30.43) | 28(60.87) | 8.587 | 0.003 | 14(30.43) | 27(58.70) | 7.436 | 0.006 | 33(71.74) | 18(39.13) | 9.900 | 0.002 |
χ2值 | 0.050 | 4.348 | 0.001 | 4.356 | 0.052 | 4.348 | |||||||
P值 | 0.822 | 0.037 | 0.999 | 0.037 | 0.819 | 0.037 |
组别 | 例数 | 胃肠道反应 | 皮疹 | 肝功能损伤 | 白细胞减少 |
---|---|---|---|---|---|
对照组 | 46 | 12(26.1) | 2(4.3) | 4(8.7) | 18(39.1) |
研究组 | 46 | 11(23.9) | 3(6.5) | 3(6.5) | 20(43.5) |
χ2值 | 0.211 | 0.198 | 0.188 | 0.176 | |
P值 | 0.865 | 0.881 | 0.901 | 0.919 |
Table 5 Comparison of incidence of adverse reactions during treatment between the two groups
组别 | 例数 | 胃肠道反应 | 皮疹 | 肝功能损伤 | 白细胞减少 |
---|---|---|---|---|---|
对照组 | 46 | 12(26.1) | 2(4.3) | 4(8.7) | 18(39.1) |
研究组 | 46 | 11(23.9) | 3(6.5) | 3(6.5) | 20(43.5) |
χ2值 | 0.211 | 0.198 | 0.188 | 0.176 | |
P值 | 0.865 | 0.881 | 0.901 | 0.919 |
组别 | 例数 | 情绪分数 | 认知分数 | 疼痛分数 | 呼吸困难分数 | 疲劳分数 |
---|---|---|---|---|---|---|
对照组 | 46 | 56.23±8.32 | 50.32±10.01 | 28.53±5.23 | 21.42±3.89 | 48.67±8.42 |
研究组 | 46 | 76.32±7.90 | 66.42±9.87 | 19.42±4.98 | 9.43±2.56 | 20.32±4.57 |
t值 | 23.341 | 21.296 | 17.456 | 26.323 | 24.121 | |
P值 | 0.001 | 0.004 | 0.009 | 0.001 | 0.001 |
Table 6 Comparison of life quality of the patients between the two groups
组别 | 例数 | 情绪分数 | 认知分数 | 疼痛分数 | 呼吸困难分数 | 疲劳分数 |
---|---|---|---|---|---|---|
对照组 | 46 | 56.23±8.32 | 50.32±10.01 | 28.53±5.23 | 21.42±3.89 | 48.67±8.42 |
研究组 | 46 | 76.32±7.90 | 66.42±9.87 | 19.42±4.98 | 9.43±2.56 | 20.32±4.57 |
t值 | 23.341 | 21.296 | 17.456 | 26.323 | 24.121 | |
P值 | 0.001 | 0.004 | 0.009 | 0.001 | 0.001 |
[1] |
|
[2] |
冀辰辰,李健斌,江泽飞. HER-2阳性乳腺癌分层治疗新策略[J]. 中国肿瘤临床,2022,49(22): 1147-1150.
|
[3] |
|
[4] |
|
[5] |
|
[6] |
李文涛. 《中国女性乳腺癌筛查标准(T/CPMA 014-2020)》解读[J]. 中华实用诊断与治疗杂志,2021,35(5): 433-435. DOI: 10.13507/j.issn.1674-3474.2021.05.001.
|
[7] |
刘秋华,林榕波. 实体瘤疗效评价标准(RECIST)指南1.1版[C]. //第十二届全国临床肿瘤大会暨2009年CSCO学术年会,2009.
|
[8] |
罗飞,梁小波. EORTC QLQ-C30在乳腺癌中的应用现状[J]. 山西医药杂志,2006,35(4): 320-322. DOI: 10.3969/j.issn.0253-9926.2006.04.018.
|
[9] |
|
[10] |
|
[11] |
张赟,王小凡. 肿瘤微环境调控癌症发生发展的研究概述[J]. 中国科学(生命科学),2022,52(9):1377-1390.
|
[12] |
|
[13] |
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[18] |
郭跃,王少波,曾昊,等. 溃疡性结肠炎相关性结肠癌与偶发性结直肠癌的差异基因分析[J]. 中国现代医药杂志,2022,24(5): 10-14.
|
[19] |
董优优,陈昌国. IFN-γ受体1与部分疾病关系的研究进展[J]. 国际检验医学杂志,2022,43(16): 2032-2037.
|
[20] |
周涵星,徐菲. 乳腺癌抗HER2单克隆抗体研究进展[J]. 中国临床新医学,2022,15(6): 488-495. DOI: 10.3969/j.issn.1674-3806.2022.06.04.
|
[21] |
|
[22] |
|
[23] |
|
[24] |
|
[25] |
|
[26] |
|
[1] | ZHOU Jing, JIA Jianguo, LIN Yixin, WU Shuang, DAI Shilong, WANG Mingjun, ZHANG Qingsong. Association of Different Metabolic Obesity Phenotypes with Breast Cancer Risk in Women: a Prospective Cohort Study [J]. Chinese General Practice, 2024, 27(02): 150-155. |
[2] | LIU Bingwei, WANG Jing, QIAO Xue, MU Silin, SHI Guangxi, LI Jingwei. Clinical Characteristics and Traditional Chinese Medicine of Hyperlipidemia in Estrogen Receptor Positive Breast Cancer Patients during Endocrine Therapy: a Real World Study [J]. Chinese General Practice, 2023, 26(36): 4558-4564. |
[3] | LI Yujing, JIN Yichao, CHEN Xing, JI Mengying, DAI Huihua. Risk Factors for Endometrial Lesions Detected by Hysteroscopy in Breast Cancer Patients Taking Tamoxifen [J]. Chinese General Practice, 2023, 26(32): 4026-4030. |
[4] | WANG Jun, WU Jiafei, WANG Yijing, ZHENG Boyue, WANG Yu, JIANG Chuanyan, LI Hui. Efficacy and Prognostic Effect of Daratumumab-based Chemotherapy Regimen in Multiple Myeloma: a Real-world Study [J]. Chinese General Practice, 2023, 26(18): 2256-2262. |
[5] | FU Shi, CHEN Chen, YU Mengzhu, JIN Changqin, HE Gan, CHU Qiao, HE Yaping. Potential Effect of Walking on Emotional Health among Breast Cancer Survivors: the Mediating Effects of Different Dimensions of Posttraumatic Growth [J]. Chinese General Practice, 2023, 26(17): 2089-2094. |
[6] | SHEN Aomei, LU Qian, FU Xin, WEI Xiaoxia, BIAN Jingru, ZHANG Liyuan, QIANG Wanmin, PANG Dong. Constructing a Risk Prediction Model of Breast Cancer-related Lymphedema Based on a Meta-analysis of Prospective Cohort Studies [J]. Chinese General Practice, 2023, 26(17): 2078-2088. |
[7] | ZHENG Qingyong, ZHAO Liang, WEI Wei, REN Xuejun, WANG Chao, SUN Rui, CONG Minghua, YU Lei, YANG Min. Mindfulness-based Stress Reduction Can Improve Psychological Condition in Breast Cancer Patients: an Overview of Systematic Reviews [J]. Chinese General Practice, 2023, 26(12): 1503-1512. |
[8] | LIU Xuewei, WANG Yuan, WEI Danmei, LU Wenli. Age-Period-Cohort Analysis of Trends of Breast Cancer Incidence and Mortality among Chinese Females from 1990 to 2019 [J]. Chinese General Practice, 2023, 26(01): 34-41. |
[9] | LAO Shen, HE Jianxing, LIANG Wenhua. Targeting Pericytes for Vascular Normalization as an Emerging Strategy in Remodeling Tumor Microenvironment [J]. Chinese General Practice, 2022, 25(32): 3971-3977. |
[10] | Xiaoyue SUN, Fengling WANG, Aihua WANG. Research Progress on the Pathogenesis and Preventive Treatment of Ischemic Stroke in Breast Cancer-related Ischemic Stroke [J]. Chinese General Practice, 2022, 25(29): 3710-3714. |
[11] | Jiahui MA, Guolian LIU, Lianhua ZHENG, Yaru BAI, Juanjuan MAI, Wenlian YAO. Breast Cancer Prevention and Treatment Behaviors in Community-living Women: Latent Class Analysis and Influencing Factors [J]. Chinese General Practice, 2022, 25(28): 3515-3522. |
[12] | Ziqiang HONG, Dacheng JIN, Xiangdou BAI, Baiqiang CUI, Yunjiu GOU. Recent Advances in the Diagnosis and Management of Multiple Primary Lung Cancer [J]. Chinese General Practice, 2022, 25(27): 3435-3442. |
[13] |
CHEN Xiaofeng, WANG Meng, LI Zhongyu, LI Jiajia.
Clinical Study of Venetoclax with Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia [J]. Chinese General Practice, 2022, 25(08): 957-962. |
[14] | WU Yanqi,LUO Ting. Research Progress in the Treatment of Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive Breast Cancer [J]. Chinese General Practice, 2021, 24(8): 1028-1032. |
[15] | GAO Ying,WEI Wei,ZHANG Peng,ZHANG Qing. Latest Developments in Natural History and Tumor Growth Rate of Breast Cancer [J]. Chinese General Practice, 2021, 24(30): 3794-3798. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||